Ticker LaunchUplisting · WINTD
Windtree Therapeutics Inc /de/
Formerly DISCOVERY LABORATORIES INC /DE/; ANSAN PHARMACEUTICALS INC; ANSAN INC
Windtree Therapeutics Inc /de/ (WINTD), already reporting to the SEC, moved up to Nasdaq Capital Market on May 21, 2020 with an offering at $7.25 per share raising $20M. Ladenburg Thalmann was lead-left underwriter. Troutman Pepper advised the company and Ellenoff Grossman & Schole advised the underwriters.
Windtree Therapeutics Inc. is a clinical-stage biopharmaceutical and medical device company developing treatments for acute cardiovascular and pulmonary diseases. Its lead cardiovascular candidate, istaroxime, targets acute heart failure and cardiogenic shock, and its lead pulmonary candidate is AEROSURF, a drug and device combination.
- Status
- Uplisting
- Ticker
- WINTD
- Exchange
- Nasdaq Capital Market
- Listed
- May 21, 2020
- Price
- $7.25
- Raised
- $20M
- Market cap at IPO price
- $119.3M
- First filed
- Apr 5, 2017
- Underwriters
- Ladenburg Thalmann
- Company counsel
- Troutman Pepper
- Underwriters' counsel
- Ellenoff Grossman & Schole
- Sector
- Biotech & pharma
- Country / state
- PA
More on this listing for subscribers
- Shares offered, over-allotment and shares outstanding after the offering
Every record in the database also has its full filing timeline, a daily-updated calendar, watchlist alerts and Excel export.
Then $99/month or $999/year. Cancel anytime.
Filings
- Registration statement (S-1) first filed Apr 5, 2017
- Latest amendment May 19, 2020
- Final prospectus (424B4) May 21, 2020
- All filings on EDGAR CIK 946486
Other Biotech & pharma uplistings in 2020
- Nomad Power Solutions, Inc.LIXT · Nov 27, 2020
- Processa Pharmaceuticals, Inc.PCSA · Oct 5, 2020 · $19.2M
- GeoVax Labs, Inc.GOVX · Sep 28, 2020 · $12.8M
- Biovie Inc.BIVI · Sep 18, 2020 · $15.7M
- Panbela Therapeutics, Inc.SNBP · Aug 31, 2020
- Scienture Holdings, Inc.MEDS · Feb 14, 2020 · $5.2M